Literature DB >> 17420370

Dengue-associated maculopathy.

Kristine Enrile Bacsal1, Soon-Phaik Chee, Ching-Li Cheng, John Vincent Policarpio Flores.   

Abstract

OBJECTIVE: To describe the clinical spectrum of fundus manifestations and angiographic and optical coherence tomographic features of dengue-associated maculopathy in a large series.
METHODS: We reviewed clinical records of patients diagnosed as having dengue maculopathy at the Singapore National Eye Centre between January 1, 2002, and December 31, 2005.
RESULTS: We identified 41 patients with serological evidence of dengue fever who had ocular signs and symptoms not attributable to other diseases within 1 month after onset of symptoms of dengue. Seventy-one eyes had maculopathy. Mean best-corrected visual acuity in the affected eye was 20/40 (range, hand motions to 20/20). Intraretinal hemorrhages were seen in 45% of eyes, usually in association with venous sheathing. Fundus fluorescein angiography demonstrated venular occlusion in 25% or arteriolar and/or venular leakage in 3% and 13%, respectively. Yellow subretinal dots were an unusual finding in 28%. Of these, 50% showed corresponding hypofluorescent spots on indocyanine green angiography. Central or paracentral scotomas were observed in 63%. Twenty-eight patients received steroid treatment. Mean visual acuity showed significant improvement between weeks 2 and 4, with an increasing proportion of eyes achieving a best-corrected visual acuity of 20/40 or better across time.
CONCLUSION: Fundus fluorescein and indocyanine green angiography, optical coherence tomography, and visual field testing are useful tools in the diagnosis of dengue maculopathy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17420370     DOI: 10.1001/archopht.125.4.501

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  38 in total

Review 1.  Emergence of the severe syndrome and mortality associated with dengue and dengue-like illness: historical records (1890 to 1950) and their compatibility with current hypotheses on the shift of disease manifestation.

Authors:  Goro Kuno
Journal:  Clin Microbiol Rev       Date:  2009-04       Impact factor: 26.132

Review 2.  Novel infectious agents causing uveitis.

Authors:  Moncef Khairallah; Soon Phaik Chee; Sivakumar R Rathinam; Sonia Attia; Venu Nadella
Journal:  Int Ophthalmol       Date:  2009-08-27       Impact factor: 2.031

3.  Macular phlebitis in a case of dengue retinopathy.

Authors:  Sangeeta Roy; Brijesh Takkar; Rohan Chawla; Atul Kumar
Journal:  BMJ Case Rep       Date:  2017-07-06

4.  Clinical and laboratory features that differentiate dengue from other febrile illnesses in an endemic area--Puerto Rico, 2007-2008.

Authors:  Christopher J Gregory; Luis Manuel Santiago; D Fermin Argüello; Elizabeth Hunsperger; Kay M Tomashek
Journal:  Am J Trop Med Hyg       Date:  2010-05       Impact factor: 2.345

5.  Dengue Stings the Eye!

Authors:  Sumana J Kamath; Madhurima K Nayak; Ruchi Gour; Neha Singh
Journal:  J Clin Diagn Res       Date:  2017-09-01

6.  In vivo infection by a neuroinvasive neurovirulent dengue virus.

Authors:  Myriam Lucia Velandia-Romero; Orlando Acosta-Losada; Jaime E Castellanos
Journal:  J Neurovirol       Date:  2012-07-24       Impact factor: 2.643

7.  Dengue Maculopathy with Foveolitis in a Postpartum Female.

Authors:  Kok Wei Kan; Patrick Sylves; Nik-Lah Nik-Ahmad-Zuky; Ismail Shatriah
Journal:  Cureus       Date:  2017-12-13

8.  Emergent infectious uveitis.

Authors:  Moncef Khairallah; Bechir Jelliti; Salah Jenzeri
Journal:  Middle East Afr J Ophthalmol       Date:  2009-10

Review 9.  [Tropical ophthalmology : Intraocular inflammation caused by "new" infectious pathogens and travel-related infections].

Authors:  U Pleyer; V Klauß; H Wilking; M M Nentwich
Journal:  Ophthalmologe       Date:  2016-01       Impact factor: 1.059

10.  Bilateral periorbital ecchymosis in a case with dengue fever.

Authors:  Vinod Kumar; Basudeb Ghosh; Usha K Raina; Neha Goel
Journal:  Indian J Ophthalmol       Date:  2009 May-Jun       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.